Inetetamab combined with S-1 and oxaliplatin as first-line treatment for human epidermal growth factor receptor 2-positive gastric cancer

Table 2 Occurrence of adverse events in the inetetamab combined with S-1 plus oxaliplatin group and the trastuzumab combined with S-1 plus oxaliplatin group, n (%)

AEs	Inetetamab group (n = 18)		Trastuzumab group (n = 19)
	All AEs	≥ Grade 3 AE	All AEs	≥ Grade 3 AE
Leukopenia	15 (83)	4 (22)	15 (79)	3 (16)
Reduction in hemoglobin	11 (61)	0	10 (53)	1 (5)
Thrombocytopenia	4 (22)	1 (6)	7 (37)	1 (5)
Nausea	15 (83)	4 (22)	16 (84)	2 (11)
Vomiting	7 (39)	0	5 (26)	1 (5)
Diarrhea	2 (11)	0	2 (11)	0
Anorexia	11 (61)	1 (6)	6 (32)	1 (5)
Abnormal liver function	3 (17)	0	3 (16)	0
Cardiotoxicity	1 (6)	0	2 (11)	0
Numbness in hands and feet	3 (17)	0	2 (11)	0
Allergic reaction	1 (6)	0	0	0
Fever	0	0	2 (11)	0

AEs: Adverse events.